[HTML][HTML] Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure
T Prébet, SD Gore, B Esterni, C Gardin… - Journal of Clinical …, 2011 - ncbi.nlm.nih.gov
T Prébet, SD Gore, B Esterni, C Gardin, R Itzykson, S Thepot, F Dreyfus, OB Rauzy…
Journal of Clinical Oncology, 2011•ncbi.nlm.nih.govPurpose Azacitidine (AZA) is the current standard of care for high-risk (ie, International
Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but
most patients will experience primary or secondary treatment failure. The outcome of these
patients has not yet been described.
Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but
most patients will experience primary or secondary treatment failure. The outcome of these
patients has not yet been described.
Abstract
Purpose
Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been described.
ncbi.nlm.nih.gov